TUDCA for Liver Health: What Human Studies Have Measured
Table of contents
- What to know
- Does TUDCA Help the Liver?
- What Have Human Studies of TUDCA and the Liver Measured?
- Does TUDCA Improve Liver Function?
- Is TUDCA Good for Fatty Liver?
- Can TUDCA Repair or Regenerate the Liver?
- Can TUDCA Cause Liver Damage?
- Does TUDCA Protect the Liver From Alcohol or Medicines?
- Is TUDCA FDA Approved for the Liver?
- TUDCA vs Milk Thistle for the Liver
- Where Does TUDCA Fit for Liver Health?
- In Summary: TUDCA for Liver Health
- Frequently Asked Questions
- References
In people with liver disease, liver enzymes fell on TUDCA in several studies, and fell more than on placebo in the one placebo-controlled trial. It has not been tested as a treatment for fatty liver, and most claims that it repairs or regenerates the liver come from studies in rats, mice and cells.
What to know
- In a placebo-controlled trial of 150 people with hepatitis C, liver enzymes fell more on TUDCA over six months.
- The liver trials were in people with diagnosed liver disease, so results can't be assumed for healthy livers.
- We found no published trial of TUDCA as a fatty liver treatment; in a four-week trial, liver fat did not change.
- Liver "regeneration" and "repair" findings come from animal studies, not from trials in people.
- We found no published report of liver injury blamed on TUDCA, though the label lists situations to avoid.
Search for TUDCA and the liver and the results promise a great deal: liver repair, regeneration, detox and protection from alcohol or medicines. Some of those claims trace back to experiments in rats or liver cells, and a few of the top results even describe TUDCA as an FDA-approved liver drug, which it is not.
This guide sets out what studies in people have actually measured, what has only been seen in animals, and what is known about whether TUDCA can harm the liver. If you have raised liver tests, it also explains where a supplement does and doesn't fit.
Does TUDCA Help the Liver?
In people with liver disease, TUDCA has lowered liver enzymes, the blood markers that rise when liver cells are irritated or damaged. In a placebo-controlled trial of 150 people with chronic hepatitis C, liver enzymes fell more on 500 or 750 mg a day than on placebo over six months [1]. In primary biliary cholangitis, a chronic disease of the small bile ducts [2], enzymes fell at doses of 500 to 1,500 mg a day [3].
Those results come from people with diagnosed liver conditions, under medical care. They show that TUDCA can change liver blood tests in those conditions. They don't show what it does for a healthy liver, and as a supplement, TUDCA is used to support normal liver function rather than to treat liver disease.
What Have Human Studies of TUDCA and the Liver Measured?
The table below lists the main studies of TUDCA in people with liver conditions. Our review of the human research on TUDCA appraises each one in detail.
| Condition | Who and how many | Dose and length | What was found |
|---|---|---|---|
| Chronic hepatitis C | 150 people, placebo-controlled | 500 or 750 mg a day, 6 months | Liver enzymes fell more than on placebo |
| Hepatitis C, added to interferon | 106 people | 10 mg per kg a day, 6 months | No difference in normal ALT, the virus or liver tissue |
| Primary biliary cholangitis | 24 people, three doses | 500 to 1,500 mg a day, 6 months | Liver enzymes fell at every dose |
| Primary biliary cholangitis | 199 people, against UDCA (ursodiol, a long-established prescription bile acid) | 750 mg a day, 24 weeks | Similar on the main liver test; two other enzymes fell more on UDCA |
| Primary biliary cholangitis | Two smaller trials against UDCA (23 and 30 people) | 500 mg a day or 12 to 15 mg per kg a day, 6 months | No difference in one; UDCA improved liver tests more in the other |
| Cirrhosis | Two very small studies | Up to 6 months | Better liver tests, without a proper comparison between groups |
| Liver transplant | 33 people | 500 mg a day, 12 months | No difference in graft function, rejection or survival |
| Obesity and insulin resistance | 20 adults, placebo-controlled | 1,750 mg a day, 4 weeks | Liver fat and liver enzymes did not change |
The sources for each row are: hepatitis C [1, 4]; primary biliary cholangitis [3, 5, 6, 7]; cirrhosis [8, 9]; transplant [10]; and obesity [11].
Does TUDCA Improve Liver Function?
The studies above measured liver enzymes, which are a sign of liver irritation rather than a direct measure of how well the liver works [12]. In fatty liver, liver specialists accept that a falling ALT can reflect improvement in disease activity, but it doesn't show on its own that scarring has improved [13]. In the TUDCA trials, results were mostly reported as enzyme changes.
Raised liver enzymes have many possible causes, from fatty liver and alcohol to medicines and hepatitis [12]. Finding the cause matters more than lowering the number. Our guide to elevated liver enzymes explains the usual next steps.
Is TUDCA Good for Fatty Liver?
We found no published trial testing TUDCA as a treatment for fatty liver in people. In the one placebo-controlled trial that measured liver fat, adults with obesity took 1,750 mg a day for four weeks, and their liver fat, about 14% at the start, did not change [11]. One trial involving TUDCA and fatty liver is registered in China, in breastfeeding mothers. It was listed as not yet recruiting when we checked in October 2026, and it does not measure liver fat [14].
The fatty liver claims you will read online come from animal research. In obese mice, TUDCA lowered blood sugar, reduced fat in the liver and brought liver enzymes back toward normal [15]. Results in mice may not carry over to people.
For fatty liver in people, losing at least 3 to 5% of body weight can reduce liver fat [16], and diet and regular exercise form the foundation of treatment [13]. Our fatty liver diet guide covers what to eat.
Can TUDCA Repair or Regenerate the Liver?
We found no controlled study in people showing that TUDCA repairs or regenerates the liver. A few human studies looked at liver tissue: in five people with hepatitis C, a marker of liver cell growth rose, with no comparison group [17]; in 106 people on interferon, liver biopsies looked the same with or without TUDCA [4]; and in cirrhosis, markers of scarring did not change [9].
The "regeneration" findings that rank in search results come from rats and mice, for example after part of the liver was surgically removed [18]. Those experiments help researchers understand how bile acids work, but they are not evidence that a supplement repairs a human liver.
Recommended to you
Post-Gallbladder Bile & Liver Support
- Restore Bile Fluidity
- Improve Fat Breakdown
- Support Liver Cells
Can TUDCA Cause Liver Damage?
We found no published report of liver injury blamed on TUDCA. In the one case report of liver injury in someone taking it, doctors attributed the injury to a different drug taken at the same time [19]. In FDA's databases of reported side effects, every report with a liver term listed several products. In one supplement report, a multi-ingredient product containing TUDCA was among seven suspected products; in the medicine reports, TUDCA was never the suspected cause [20, 21]. These reports have no denominator and cannot show cause.
The federal LiverTox database has no chapter on TUDCA, which means it hasn't been reviewed there, not that it has been cleared. In controlled trials lasting up to 54 weeks, side effects were about as common on TUDCA as on placebo or on UDCA, and the ones reported most often were digestive [22, 5, 23].
The Italian medicine label says TUDCA should not be taken with a blocked bile duct, acute inflammation of the gallbladder or bile ducts, or frequent gallbladder attacks, and it advises liver tests every four weeks for the first three months of treatment, then every three months [24]. Signs of liver injury from a medicine or supplement include yellowing of the skin or eyes, dark urine, unusual tiredness and itching, and they need a doctor [25].
Does TUDCA Protect the Liver From Alcohol or Medicines?
We found no study in people testing whether TUDCA protects the liver from alcohol, anabolic steroids or medicines. The idea comes from cell and animal experiments [26], and some online forums describe TUDCA as protection for the liver during heavy drinking or steroid use. The Italian label points the other way, advising against taking TUDCA together with drugs that can harm the liver [24].
If you drink alcohol or take a medicine that affects the liver, TUDCA is not a reason to take more of either. Our guide to alcohol after gallbladder removal covers drinking safely.
Is TUDCA FDA Approved for the Liver?
No. In the US, TUDCA is sold as a dietary supplement, and the FDA does not approve supplements before they go on sale [27]. Some pages that rank for TUDCA say it is FDA approved for liver disease, but that approval belongs to UDCA, the closely related bile acid sold by prescription as ursodiol.
Ursodiol is a long-established medicine, first approved in 1987 [28], and it is the first-line treatment for primary biliary cholangitis [2]. If your doctor has prescribed it, keep taking it as directed; TUDCA is not a substitute for it.
TUDCA vs Milk Thistle for the Liver
Milk thistle is a plant extract and TUDCA is a bile acid, so they are different things with different research. Trials of milk thistle in liver disease have given conflicting or limited results [29], and we found no trial comparing the two. Our comparison of TUDCA vs milk thistle goes through both.
Where Does TUDCA Fit for Liver Health?
As a supplement, TUDCA is used to support normal liver function and healthy bile flow. That is especially relevant after gallbladder removal, when bile flows directly from the liver into the small intestine instead of being stored [30]. Dr.Primal's TUDCA is made for life after gallbladder removal and taken with meals, to support healthy bile flow and fat digestion. Our guide to whether not having a gallbladder affects your liver covers what changes.
In Summary: TUDCA for Liver Health
In people with liver disease, liver enzymes fell on TUDCA in several studies, and more than on placebo in the one placebo-controlled trial, but it has not been tested as a treatment for fatty liver, and claims that it repairs the liver come from animal studies. We found no published report of liver injury blamed on it, and the label lists the situations in which it should not be taken.
If you are working out what is behind your symptoms after meals, our digestion quiz is a quick way to put your symptoms and habits in order.
Frequently Asked Questions
When should I not take TUDCA?
The Italian label says not to take it in pregnancy, while breastfeeding, with an active peptic ulcer, with frequent gallbladder attacks, or with acute inflammation or blockage of the gallbladder or bile ducts [24]. It also advises against it after surgery that removed part of the lower small intestine.
What should you not take TUDCA with?
The Italian label advises keeping it two hours apart from bile acid binders such as cholestyramine and from aluminum antacids, monitoring cyclosporine, and avoiding estrogens, hormonal contraceptives, some cholesterol-lowering drugs and drugs that can harm the liver [24]. No study in people has tested these interactions.
Is it okay to take TUDCA every day?
In trials, people took TUDCA daily for months, and in some studies for about a year, and side effects were about as common as on placebo or UDCA [22, 5, 23]. Those trials were in people with specific conditions. Our guide to how long to take TUDCA covers long-term use.
Is TUDCA good for liver cirrhosis?
References
- Crosignani A, Budillon G, Cimino L, et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepatogastroenterology. 1998;45(23):1624-1629. PubMed
- Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. PubMed
- Crosignani A, Battezzati PM, Setchell KD, et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci. 1996;41(4):809-815. PubMed
- Gracielle P, et al (author names as indexed). A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: an interferon sparing effect of t-UDCA. Hepatol Res. 2002;23(4):227-236. PubMed
- Ma H, Zeng M, Han Y, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016;95(47):e5391. PubMed
- Larghi A, Crosignani A, Battezzati PM, et al. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Aliment Pharmacol Ther. 1997;11(2):409-414. PubMed
- Ferri F, Bernocchi P, Fedeli S. [Taurodeoxycholic acid in the treatment of primary biliary cirrhosis. A controlled study in comparison to ursodeoxycholic acid]. Clin Ter. 1993;143(4):321-326. PubMed
- Caglieris S, Giannini E, Dardano G, Mondello L, Valente U, Testa R. Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists. Hepatogastroenterology. 2000;47(34):1045-1047. PubMed
- Pan XL, Zhao L, Li L, et al. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci. 2013;33(2):189-194. PubMed
- Angelico M, Tisone G, Baiocchi L, et al. One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation. Ital J Gastroenterol Hepatol. 1999;31(6):462-468. PubMed
- Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899-1905. PubMed
- Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35. PubMed
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. PubMed
- ClinicalTrials.gov. Maternal oral TUDCA in high-risk lactating mother-infant dyads identified by early postpartum breast milk bile acid hydrophobicity index. NCT07517276. Peking University First Hospital. Not yet recruiting. Accessed October 21, 2026. ClinicalTrials.gov
- Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137-1140. PubMed
- National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for NAFLD & NASH. Last reviewed April 2021. NIDDK
- Panella C, Ierardi E, De Marco MF, et al. Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease? Ital J Gastroenterol. 1995;27(5):256-258. PubMed
- Bai C, Song X, Yan J, et al. Tauroursodeoxycholic Acid Induces Liver Regeneration and Alleviates Fibrosis Through GATA3 Activation. Biomedicines. 2025;13(4):10.3390/biomedicines13040910. PubMed
- Satinsky A, Mayer N, Swanson C, Sasso B. Fenbendazole-Associated Drug-Induced Liver Injury with Concomitant Use of Tauroursodeoxycholic Acid. ACG Case Rep J. 2026;13(7):e02222. PubMed
- US Food and Drug Administration. openFDA food adverse event endpoint (CAERS reports for foods and dietary supplements), data as of July 7, 2026. Searched October 17, 2026. openFDA
- US Food and Drug Administration. openFDA drug adverse event endpoint (FAERS reports), data as of July 30, 2026. Searched October 17, 2026. openFDA
- Elia AE, Lalli S, Monsurrò MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45-52. PubMed
- Ladakis DC, Harrison KL, Smith MD, et al. Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med. 2025;6(3):100522. PubMed
- Agenzia Italiana del Farmaco. Tudcabil 250 mg capsule rigide: riassunto delle caratteristiche del prodotto (summary of product characteristics). Bruschettini S.r.l.; made available by AIFA January 31, 2021. AIFA
- MedlinePlus. Drug-induced liver injury. National Library of Medicine. Reviewed October 30, 2024. MedlinePlus
- Paridaens A, Raevens S, Colle I, et al. Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication. Liver Int. 2017;37(5):748-756. PubMed
- US Food and Drug Administration. Questions and answers on dietary supplements. Content current as of August 27, 2026. FDA
- US Food and Drug Administration. Drugs@FDA: Actigall (NDA 019594, approved 1987) and URSO 250 / URSO Forte (NDA 020675, approved 1997). Accessed October 20, 2026. Drugs@FDA
- National Center for Complementary and Integrative Health. Milk thistle. Last updated February 2025. NCCIH
- National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for gallstones. Last reviewed November 2017. NIDDK
- Lamm V, Huang K, Deng R, et al. Tauroursodeoxycholic Acid (TUDCA) Reduces ER Stress and Lessens Disease Activity in Ulcerative Colitis. medRxiv. 2025. Preprint posted April 4, 2025. doi:10.1101/2025.04.02.25322684. PubMed
- Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK). Taurolite 250 mg kapsül: kısa ürün bilgisi (summary of product characteristics). Bio-Gen İlaç. Accessed October 17, 2026. TITCK
This article is for general education and is not a substitute for advice from your doctor. TUDCA is sold as a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.